These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 22803494)

  • 1. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy.
    Ward F; Dunne O; Crotty TB; Fennelly D; Watson A; Holian J
    Ir Med J; 2012 May; 105(5):148-9. PubMed ID: 22803494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cut-off hemodialysis and bortezomib-based therapy to rescue kidneys in myeloma-dependent cast nephropathy.
    Sinisalo M; Silvennoinen R; Wirta O
    Am J Hematol; 2012 Jun; 87(6):640. PubMed ID: 22473521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis.
    Hutchison CA; Heyne N; Airia P; Schindler R; Zickler D; Cook M; Cockwell P; Grima D
    Nephrol Dial Transplant; 2012 Oct; 27(10):3823-8. PubMed ID: 22273664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Improved prognosis in light chain nephropathy due to multiple myeloma].
    Juul JS; Larsen T; Marcussen N; Pedersen EB
    Ugeskr Laeger; 2012 Apr; 174(17):1159-60. PubMed ID: 22533933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment by long haemodialysis sessions with high cut-off filters in myeloma cast nephropathy: our experience.
    Borrego-Hinojosa J; Pérez-del Barrio MP; Biechy-Baldan Mdel M; Merino-García E; Sánchez-Perales MC; García-Cortés MJ; Ocaña-Pérez E; Gutiérrez-Rivas P; Liébana-Cañada A
    Nefrologia; 2013; 33(4):515-23. PubMed ID: 23897183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
    Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
    Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of blood purification and bortezomib plus dexamethasone therapy for the treatment of acute renal failure due to myeloma cast nephropathy.
    Hasegawa M; Kondo F; Yamamoto K; Murakami K; Tomita M; Nabeshima K; Nakai S; Kato M; Ohashi A; Arai J; Hiki Y; Ishii J; Emi N; Sugiyama S; Yuzawa Y
    Ther Apher Dial; 2010 Oct; 14(5):451-6. PubMed ID: 21175542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended high cut-off haemodialysis for myeloma cast nephropathy in Auckland, 2008-2012.
    Tan J; Lam-Po-Tang M; Hutchison CA; de Zoysa JR
    Nephrology (Carlton); 2014 Jul; 19(7):432-5. PubMed ID: 24931113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis.
    Krieter DH; Devine E; Wanner C; Storr M; Krause B; Lemke HD
    Artif Organs; 2014 Oct; 38(10):888-93. PubMed ID: 24392952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
    Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
    Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management options for cast nephropathy in multiple myeloma.
    Cockwell P; Hutchison CA
    Curr Opin Nephrol Hypertens; 2010 Nov; 19(6):550-5. PubMed ID: 20827195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal improvement in myeloma with plasma exchange.
    Haspel RL; Cserti-Gazdewich C; Dzik WH
    N Engl J Med; 2011 Sep; 365(11):1061-2; author reply 1062. PubMed ID: 21916653
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal improvement in myeloma with bortezomib plus plasma exchange.
    Burnette BL; Leung N; Rajkumar SV
    N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal improvement in myeloma with plasma exchange.
    Hutchison C; Bridoux F; Fermand JP
    N Engl J Med; 2011 Sep; 365(11):1061; author reply 1062. PubMed ID: 21916654
    [No Abstract]   [Full Text] [Related]  

  • 15. High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.
    Hutchison CA; Cockwell P; Moroz V; Bradwell AR; Fifer L; Gillmore JD; Jesky MD; Storr M; Wessels J; Winearls CG; Weisel K; Heyne N; Cook M
    Lancet Haematol; 2019 Apr; 6(4):e217-e228. PubMed ID: 30872075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of acute kidney injury with cast nephropathy.
    Walther C; Podoll AS; Finkel KW
    Clin Nephrol; 2014 Jul; 82(1):1-6. PubMed ID: 24725380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
    de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
    Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
    [No Abstract]   [Full Text] [Related]  

  • 18. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney.
    Cockwell P; Cook M
    Adv Chronic Kidney Dis; 2012 Sep; 19(5):324-32. PubMed ID: 22920643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury.
    Yadav P; Hutchison CA; Basnayake K; Stringer S; Jesky M; Fifer L; Snell K; Pinney J; Drayson MT; Cook M; Cockwell P
    Eur J Haematol; 2016 Jun; 96(6):610-7. PubMed ID: 26248588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lambda light chain myeloma with oliguric cast nephropathy and remission with bortezomib, doxorubicin and dexamethasone.
    Hada R; Poudyal B; Sharma A; Khatri R
    JNMA J Nepal Med Assoc; 2012; 52(188):192-5. PubMed ID: 23591252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.